Products
Suppliers
Sourcing Requests

Post Sourcing Request Exhibition

Home
Products
Supplier
E-Trade Season
Content Hub
Industry Insights
Service & Membership
For Supplier

My Account

My Online Store

My EZSourcing

View Sourcing Requests

Customer Service
For Buyer

Search Products & Suppliers
Products Directory Suppliers Discovery Post EZSourcing
Service
Buyer Sourcing Event Contact Us
Quick links
My Favorites Recent Visit History

You are here: Industry Insights > ICP-033

News List

InnoCare Announces Dosing of First Patient in Clinical Trial of RTK Inhibitor ICP-033 in China PharmaSources.com
March 30, 2022
InnoCare Pharma (HKEX: 09969), a leading biopharmaceutical company focusing on cancer and autoimmune diseases...
InnoCare Announces Approval of Initiation of Phase 1 Clinical Trial of RTK Inhibitor ICP-033 in China prnasia
June 28, 2021
InnoCare, a leading biopharmaceutical company focusing on cancer and autoimmune diseases, announced that China's National Medical Products Administration (NMPA) has approved the initiation of a Phase I clinical trial of ICP-033, the Company's novel ...

Contact Us

PharmaSources@imsinoexpo.com

Tel: (+86) 400 610 1188

WhatsApp/Telegram/Wechat: +86 13621645194

About Us: About PharmaSources; Terms of Service; Privacy Policy; Intellectual Property; Media Partners

Buy: Search Products; Post Sourcing Requests; Search Suppliers; CAS Search

Sell: Member Application; Advertising; Post Products; EZSourcing

Events: CPHI China; PMEC China; Conferences; Search Events

Help: FAQ; Contact Us; Feedback

Copyright 2006-2024 Shanghai Sinoexpo Informa Markets International Exhibition Co. Ltd (All Rights Reserved) 沪ICP备05034851号-182 沪公网安备31010402010101号
Links：
CCCMHPIE SJGLE.com JJGLE.COM JDGLE.COM XIUGLE.COM DENGGLE.COM HPGLE.COM
Follow Us：
Pharma Sources Insight June 2024: Globalization on the Go

PharmaSources Customer Service